0001209191-16-133579.txt : 20160721
0001209191-16-133579.hdr.sgml : 20160721
20160721123709
ACCESSION NUMBER: 0001209191-16-133579
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20140930
FILED AS OF DATE: 20160721
DATE AS OF CHANGE: 20160721
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ACUCELA INC.
CENTRAL INDEX KEY: 0001400482
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 020592619
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1301 SECOND AVE.
STREET 2: SUITE 4200
CITY: SEATTLE
STATE: WA
ZIP: 98101
BUSINESS PHONE: 206-805-8300
MAIL ADDRESS:
STREET 1: 1301 SECOND AVE.
STREET 2: SUITE 4200
CITY: SEATTLE
STATE: WA
ZIP: 98101
FORMER COMPANY:
FORMER CONFORMED NAME: Acucela Inc
DATE OF NAME CHANGE: 20070523
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: SBI Investment Co., Ltd.
CENTRAL INDEX KEY: 0001598705
STATE OF INCORPORATION: M0
FISCAL YEAR END: 0331
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-55133
FILM NUMBER: 161776949
BUSINESS ADDRESS:
STREET 1: IZUMI GARDEN TOWER 19F, 1-6-1 ROPPONGI
STREET 2: MINATO-KU
CITY: TOKYO
STATE: M0
ZIP: 106-6019
BUSINESS PHONE: 81-3-6229-0127
MAIL ADDRESS:
STREET 1: IZUMI GARDEN TOWER 19F, 1-6-1 ROPPONGI
STREET 2: MINATO-KU
CITY: TOKYO
STATE: M0
ZIP: 106-6019
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: SBI Capital Management Co., Ltd.
CENTRAL INDEX KEY: 0001598959
STATE OF INCORPORATION: M0
FISCAL YEAR END: 0331
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-55133
FILM NUMBER: 161776950
BUSINESS ADDRESS:
STREET 1: IZUMI GARDEN TOWER 19F
STREET 2: 1-6-1 ROPPONGI, MINATO-KU
CITY: TOKYO
STATE: M0
ZIP: 106-6019
BUSINESS PHONE: 81-3-6229-0127
MAIL ADDRESS:
STREET 1: IZUMI GARDEN TOWER 19F
STREET 2: 1-6-1 ROPPONGI, MINATO-KU
CITY: TOKYO
STATE: M0
ZIP: 106-6019
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: SBI Holdings, Inc.
CENTRAL INDEX KEY: 0001446698
STATE OF INCORPORATION: M0
FISCAL YEAR END: 0331
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-55133
FILM NUMBER: 161776951
BUSINESS ADDRESS:
STREET 1: IZUMI GARDEN TOWER 19F, 1-6-1 ROPPONGI
STREET 2: MINATO-KU
CITY: TOKYO
STATE: M0
ZIP: 106-6019
BUSINESS PHONE: 81-3-6229-0122
MAIL ADDRESS:
STREET 1: IZUMI GARDEN TOWER 19F, 1-6-1 ROPPONGI
STREET 2: MINATO-KU
CITY: TOKYO
STATE: M0
ZIP: 106-6019
FORMER NAME:
FORMER CONFORMED NAME: SBI Holdings Inc/Japan
DATE OF NAME CHANGE: 20081001
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2014-09-30
0
0001400482
ACUCELA INC.
NONE
0001446698
SBI Holdings, Inc.
IZUMI GARDEN TOWER 19F, 1-6-1 ROPPONGI
MINATO-KU
TOKYO
M0
106-6019
JAPAN
0
0
1
0
0001598959
SBI Capital Management Co., Ltd.
IZUMI GARDEN TOWER 19F, 1-6-1 ROPPONGI
MINATO-KU
TOKYO
M0
106-6019
JAPAN
0
0
1
0
0001598705
SBI Investment Co., Ltd.
IZUMI GARDEN TOWER 19F, 1-6-1 ROPPONGI
MINATO-KU
TOKYO
M0
106-6019
JAPAN
0
0
1
0
Common Stock
2014-09-30
4
J
0
1111111
8.15
A
1485928
I
By SBI Incubation Co., Ltd.
Common Stock
2015-03-31
4
J
0
2036754
5.55
A
6196869
I
By SBI Capital Management Co., Ltd.
Common Stock
2015-11-30
4
J
0
69628
5.72
A
1555556
I
By SBI Incubation Co., Ltd.
Common Stock
2016-06-02
4
P
0
342500
10.08
A
1898056
I
By SBI Incubation Co., Ltd.
Common Stock
2016-06-03
4
P
0
256300
9.63
A
2154356
I
By SBI Incubation Co., Ltd.
Common Stock
2016-06-15
4
P
0
1018400
9.30
A
3172756
I
By SBI Incubation Co., Ltd.
Common Stock
2016-06-16
4
P
0
257000
11.13
A
3429756
I
By SBI Incubation Co., Ltd.
Common Stock
2016-06-17
4
P
0
776300
12.53
A
4206056
I
By SBI Incubation Co., Ltd.
Common Stock
2016-06-20
4
P
0
723200
16.03
A
4929256
I
By SBI Incubation Co., Ltd.
Common Stock
2016-06-21
4
P
0
555000
16.13
A
5484256
I
By SBI Incubation Co., Ltd.
Common Stock
2016-06-22
4
P
0
456400
16.21
A
5940656
I
By SBI Incubation Co., Ltd.
Common Stock
2016-06-23
4
P
0
991000
19.05
A
6931656
I
By SBI Incubation Co., Ltd.
Common Stock
2016-06-24
4
P
0
478600
17.67
A
7410256
I
By SBI Incubation Co., Ltd.
Common Stock
2016-06-27
4
P
0
617800
22.15
A
8028056
I
By SBI Incubation Co., Ltd.
Common Stock
2016-06-27
4
J
0
4160115
22.59
A
6196869
I
By SBI Capital Management Co., Ltd.
Common Stock
2016-06-27
4
J
0
6196869
22.59
A
14224925
D
Represents a transfer of shares of all shares of the Issuer's common stock held by SoftBank Internet Fund, an affiliated entity, to SBI Incubation Co., Ltd., another affiliated entity. As a result, SoftBank Internet Fund and Soft Trend Capital Corp., the sole general partner of SoftBank Internet Fund, ceased to be beneficial owners of the Issuer's common stock.
This Form 4 is being filed jointly by SBI Holdings, Inc., SBI Capital Management Co., Ltd. and SBI Investment Co., Ltd. Each Reporting Person disclaims beneficial ownership of these securities except to the extent of its pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purpose of Section 16 or any other purpose.
These shares are held directly by SBI Incubation Co., Ltd., which is an indirect wholly-owned subsidiary of SBI Holdings, Inc. SBI Holdings, Inc. may be deemed to be the indirect beneficial owner of these securities.
Represents a transfer of 1,257,252 shares of the Issuer's common stock held by SBI BB Media Investment Limited Partnership, and 779,502 shares of the Issuer's common stock held by SBI Broadband Fund No. 1, both affiliated entities, to SBI Capital Management Co., Ltd., another affiliated entity. As a result, SBI BB Media Investment Limited Partnership and SBI Broadband Fund No. 1 Limited Partnership ceased to be beneficial owners of the Issuer's common stock.
These shares are held directly by SBI Capital Management Co., Ltd., which is an indirect wholly-owned subsidiary of SBI Holdings, Inc. SBI Holdings, Inc. may be deemed to be the indirect beneficial owner of these securities.
Represents a transfer of all shares of the Issuer's common stock held by Trans-Science No. 2A Investment Limited Partnership, an affiliated entity, to SBI Incubation Co., Ltd., another affiliated entity. As a result, (i) SBI Transscience Co., Ltd. and (ii) Trans-Science No. 2A Investment Limited Partnership, over which SBI Transccience Co., Ltd. is the sole general partner, ceased to be beneficial owners of the Issuer's common stock.
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.34 to $11.14, exclusive of any fees, commissions or other expenses. The Reporting Persons undertake to provide the Issuer, any stockholder of the Issuer, or the Staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.57 to $9.64, exclusive of any fees, commissions or other expenses. The Reporting Persons undertake to provide the Issuer, any stockholder of the Issuer, or the Staff of the SEC, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.98 to $11.42, exclusive of any fees, commissions or other expenses. The Reporting Persons undertake to provide the Issuer, any stockholder of the Issuer, or the Staff of the SEC, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $10.46 to $12.30, exclusive of any fees, commissions or other expenses. The Reporting Persons undertake to provide the Issuer, any stockholder of the Issuer, or the Staff of the SEC, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $10.82 to $13.54, exclusive of any fees, commissions or other expenses. The Reporting Persons undertake to provide the Issuer, any stockholder of the Issuer, or the Staff of the SEC, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $15.08 to $16.41, exclusive of any fees, commissions or other expenses. The Reporting Persons undertake to provide the Issuer, any stockholder of the Issuer, or the Staff of the SEC, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $15.20 to $16.81, exclusive of any fees, commissions or other expenses. The Reporting Persons undertake to provide the Issuer, any stockholder of the Issuer, or the Staff of the SEC, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $15.57 to $16.97, exclusive of any fees, commissions or other expenses. The Reporting Persons undertake to provide the Issuer, any stockholder of the Issuer, or the Staff of the SEC, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $17.61 to $20.23, exclusive of any fees, commissions or other expenses. The Reporting Persons undertake to provide the Issuer, any stockholder of the Issuer, or the Staff of the SEC, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $15.36 to $19.56, exclusive of any fees, commissions or other expenses. The Reporting Persons undertake to provide the Issuer, any stockholder of the Issuer, or the Staff of the SEC, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $20.15 to $22.59, exclusive of any fees, commissions or other expenses. The Reporting Persons undertake to provide the Issuer, any stockholder of the Issuer, or the Staff of the SEC, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote to this Form 4.
Represents a transfer of (i) 1,777,778 shares of the Issuer's common stock held by BIOVISION Life Science Fund No. 1, (ii) 1,871,250 shares of the Issuer's common stock held by SBI Bio Life Science Investment LPS, (iii) 258,582 shares of the Issuer's common stock held by SBI BB Mobile Investment LPS, and (iv) 252,505 shares of the Issuer's common stock held by SBI Phoenix No. 1 Investment LPS, affiliated entities, to SBI Capital Management Co., Ltd. As a result, (i) BIOVISION Life Science Fund No. 1, (ii) SBI Bio Life Science Investment LPS, (iii) SBI BB Mobile Investment LPS, (iv) SBI Phoenix No. 1 Investment LPS, and (vi) SBI Investment Co., Ltd. (as the sole general partner of BIOVISION Life Science Fund No. 1, SBI Bio Life Science Investment LPS, SBI BB Mobile Investment LPS, and SBI Phoenix No. 1 Investment LPS) ceased to be beneficial owners of the Issuer's common stock.
Represents the transfer of all shares of the Issuer's common stock held by SBI Capital Management Co., Ltd. to SBI Holdings, Inc. As a result, SBI Capital Management Co., Ltd. ceased to be a beneficial owner of the Issuer's common stock.
/s/ Yoshitaka Kitao, Representative Director, President & CEO
2016-07-21